高强度聚焦超声联合吉西他滨治疗晚期胰腺癌预后的前瞻性研究简

目的 探讨高强度聚焦超声（HIFU）联合吉西他滨治疗晚期胰腺癌的预后及其影响因素.方法 选择63例胰腺癌晚期患者,均采用HIFU联合吉西他滨化疗,评价其疗效,随访0.5年及1年的生存率,收集并分析影响生存率的因素.结果 63例患者经HIFC联合吉西他滨治疗后,完全缓解0例,部分缓解7例（11.11%）,疾病稳定36例（57.14%）,疾病进展19例（30.19%）,总疾病控制率68.25%.随访期内患者总中位生存时间为6.9个月,0.5年和1年生存率分别为53.97%和9.52%.单因素和COX回归分析结果发现KPS评分与有无肝转移是影响生存率的重要危险因素.本组未发现明显严重不良反应.结论 HIFU联合吉西他滨化疗治疗晚期胰腺癌可相对延长生存时间,无严重不良反应,对KPS评分高与无肝转移患者可采取更积极的治疗态度.

A prospective study of prognosis in HIFU therapy combined with gemcitabine in advanced pancreatic cancer

Objective To investigate prognosis and its prognostic factors of HIFU therapy in combination with gemcitabine in advanced pan- creatic cancer. Methods 63 patients with advanced pancreatic cancer were collected. HIFU treatment in combination with gemcitabine chemothera- py were used and the efficacy and survival rate of O. 5 years and 1 - year was evaluated and calculated. Factors impacted survival rate were collected and analyzed. Results In 63 patient, 0 cases got complete remission under HIFC ＋ gemcitabine , partial remission in 7 cases （ 11.11% ） , stable disease in 36 cases （57.14%） , disease progression in 19 cases （30.19%）. Total disease control rate was 68.25%. Median overall survival time was a period of 6.9 months after follow - up. 0.5 year and 1 year survival rates were 53.97% and 9.52%. Univariate and COX regression analysis found that KPS score and liver metastasis were important risk factors affecting survival rate. No serious adverse reactions was found in the study. Con- elusion HIFU in combination with gemcitabine chemotherapy for advanced pancreatic cancer may relatively prolong survival time and have no serious adverse reactions. Patients with higher KPS score and no liver metastasis may take a more aggressive treatment approach.